← Eichor
Study identifier: NCT06484062 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Condition: Acute Myeloid Leukemia · Myelodysplastic Syndrome · Myelodysplastic Syndrome/Acute Myeloid Leukemia  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 1
Planned participants54
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 is a combination of two drugs, decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Giving cirtuvivint alone or in combination with ASTX727 may be safe, tolerable, and/or effective in treating patients with AML and MDS.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (22)

Yale UniversityNew Haven, Connecticut, United StatesRecruiting
Emory University Hospital/Winship Cancer InstituteAtlanta, Georgia, United StatesRecruiting
University of Chicago Comprehensive Cancer CenterChicago, Illinois, United StatesRecruiting
UC Comprehensive Cancer Center at Silver CrossNew Lenox, Illinois, United StatesSuspended
University of Chicago Medicine-Orland ParkOrland Park, Illinois, United StatesSuspended
UChicago Medicine Northwest IndianaCrown Point, Indiana, United StatesSuspended
University of Maryland/Greenebaum Cancer CenterBaltimore, Maryland, United StatesRecruiting
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting
Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, Missouri, United StatesRecruiting
Siteman Cancer Center at West County HospitalCreve Coeur, Missouri, United StatesRecruiting
Washington University School of MedicineSt Louis, Missouri, United StatesRecruiting
Siteman Cancer Center-South CountySt Louis, Missouri, United StatesRecruiting

+ 10 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06484062